Literature DB >> 3579398

Aggressive surgical approach for drug-free remission from myasthenia gravis.

J E Fischer, H T Grinvalski, M S Nussbaum, H J Sayers, R E Cole, F J Samaha.   

Abstract

A series of 27 patients with generalized myasthenia gravis is presented. All patients were treated by a sternal split and extended thymectomy and radical mediastinal dissection. The overall drug-free remission rate was 63%, although three additional patients are likely to achieve drug-free remission in the near future, with the total drug-free remission rate then being 74%. Of the remaining patients, all but three improved and require decreased medication, for an improvement rate of approximately 90%. One patient who has not improved had an invasive malignant thymoma. Drug-free remission was achieved in 46% of the male patients and in 82% of the female patients despite that the mean duration of disease was greater than 3.5 years. There was one serious complication, that of sterile sternal dehiscence. There was no mortality. The results suggest that an aggressive, radical surgical approach to myasthenia gravis, even in a group of patients considered somewhat less favorable because of a relatively long duration of disease, can result in a high percentage of drug-free remissions. Radical surgery for myasthenia gravis appears to be the treatment of choice, with medical therapy being reserved for those patients who are not likely to survive operation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3579398      PMCID: PMC1493029          DOI: 10.1097/00000658-198705000-00007

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  20 in total

1.  Distribution of thymic tissue at the anterior mediastinum. Current procedures in thymectomy.

Authors:  A Masaoka; Y Nagaoka; Y Kotake
Journal:  J Thorac Cardiovasc Surg       Date:  1975-10       Impact factor: 5.209

2.  Recurrence of thymic hyperplasia after trans-sternal thymectomy in myasthenia gravis.

Authors:  M Rosenberg; W O Jaúregui; M R Herrera; A J Roncoroni; O R Rojas; G S Olmedo
Journal:  Chest       Date:  1986-06       Impact factor: 9.410

3.  Surgical treatment in myasthenia gravis. A 27 year experience.

Authors:  H E Cohn; R W Solit; N J Schatz; N Schlezinger
Journal:  J Thorac Cardiovasc Surg       Date:  1974-12       Impact factor: 5.209

4.  Transcervical approach to the thymus and to mediastinal tumors.

Authors:  R W Riemer
Journal:  Am J Surg       Date:  1972-04       Impact factor: 2.565

5.  Thymectomy for myasthenia gravis.

Authors:  D G Mulder; C Herrmann; J Keesey; H Edwards
Journal:  Am J Surg       Date:  1983-07       Impact factor: 2.565

6.  The value of thymectomy in myasthenia gravis: a computer-assisted matched study.

Authors:  J M Buckingham; F M Howard; P E Bernatz; W S Payne; E G Harrison; P C O'Brien; L H Weiland
Journal:  Ann Surg       Date:  1976-10       Impact factor: 12.969

7.  Reoperation after transcervical thymectomy for myasthenia gravis.

Authors:  A Masaoka; Y Monden; Y Seike; T Tanioka; K Kagotani
Journal:  Neurology       Date:  1982-01       Impact factor: 9.910

8.  A prospective study of thymectomy and serum acetylcholine receptor antibodies in myasthenia gravis.

Authors:  C W Olanow; A S Wechsler; A D Roses
Journal:  Ann Surg       Date:  1982-08       Impact factor: 12.969

9.  Myasthenia gravis, thymectomy, and antiacetycholine receptor antibody.

Authors:  E Bartoccioni; F Scuderi; C Scoppetta; A Evoli; P Tonali; L Guidi; C Bartoloni; T Terranova
Journal:  J Neurol       Date:  1980       Impact factor: 4.849

10.  Thymectomy for myasthenia gravis: 14-year experience.

Authors:  J R Hankins; R F Mayer; J R Satterfield; S Z Turney; S Attar; A J Sequeira; B W Thompson; J S McLaughlin
Journal:  Ann Surg       Date:  1985-05       Impact factor: 12.969

View more
  1 in total

1.  Extended cervicomediastinal thymectomy in the integrated management of myasthenia gravis.

Authors:  G B Bulkley; K N Bass; G R Stephenson; M Diener-West; S George; P A Reilly; R R Baker; D B Drachman
Journal:  Ann Surg       Date:  1997-09       Impact factor: 12.969

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.